The effects of state pharmacy drug product selection laws on statin patient generic-to-branded drug switch-backs
Year of publication: |
2015
|
---|---|
Authors: | Chressanthis, George A. ; Dahan, Nayla G. ; Fandl, Kevin J. |
Published in: |
The American economist : journal of Omnicron Delta Epsilon, the International Honor Society in Economics. - Los Angeles : SAGE, ISSN 0569-4345, ZDB-ID 281405-5. - Vol. 60.2015, 1, p. 26-51
|
Subject: | state pharmacy drug product selection laws | generic-to-branded drug switch-backs | statin patients | generic therapeutic interchange and substitution | health economics | Arzneimittel | Pharmaceuticals | Gesundheitskosten | Health care costs | Pharmaindustrie | Pharmaceutical industry | Drogenkonsum | Drug consumption | Arzneimittelmarkt | Pharmaceutical market | Pharmahandel | Pharmaceutical distributors | Droge | Drug | Patienten | Patients | Drogenpolitik | Drug policy |
-
Strategic submissions: a cross-country analysis of supplemental drug approvals
Dubois, Pierre, (2023)
-
Drugs, guns, and targeted competition
Dubovik, Andrei, (2014)
-
Essential and orphan drugs in Panama : perception of competition and implications of pricing policy
Herrera Ballesteros, VĂctor H., (2020)
- More ...
-
Up in Smoke : International Treaty Obligations and Marijuana Reform in the United States
Fandl, Kevin J., (2021)
-
Fandl, Kevin J., (2010)
-
Adios embargo : the case for executive termination of the U.S. embargo on Cuba
Fandl, Kevin J., (2017)
- More ...